Ensodata Announces Collaboration with Takeda to Improve Type 1 Diagnostic Journey
AI-based polysomnography (PSG) algorithm to be developed, validated, and integrated into EnsoData’s EnsoSleep AI Scoring and Study Management platform
Partnership offers potential to enable accurate, scalable NT1 identification earlier in the care journey using PSG and address the unmet need for more timely diagnosis
MADISON, Wis. – August 21, 2025 – Today, EnsoData, a pioneer in healthcare AI, announces a collaboration with Takeda to jointly develop and validate AI-based polysomnography (PSG) algorithms to support more accurate and scalable diagnosis of narcolepsy type 1 (NT1). Upon successful validation and regulatory clearance, EnsoData will pursue the clinical availability and release of AI algorithms to enable future access, use, and support for healthcare professionals that care for patients with sleep problems. As part of future releases, the algorithms will be integrated into EnsoData’s cloud platform for sleep study data viewing, reporting, and analysis tools to expand AI capabilities and enhance clinical workflows for NT1 diagnosis and follow-up care.
